Search research articles
Contact Us
Filters
Showing results (1-10 of 45) with videos related to
Page
of 5
Sort By:
Review of Agricultural, Food and Environmental Studies
|
January 23, 2023
The new Common Agricultural Policy: reflecting an agro-ecological transition. The legal perspective
Alexandra Langlais
The European Respiratory Journal
|
June 2, 2016
Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?
Jacques Cadranel, Marie Wislez, Alexandra Langlais, et al.
Environmental Science and Pollution Research International
|
August 7, 2023
Linking ecotoxicological effects on biodiversity and ecosystem functions to impairment of ecosystem services is a challenge: an illustration with the case of plant protection products
Stéphane Pesce, Annette Bérard, Marie-Agnès Coutellec, et al.
Respiratory Medicine and Research
|
June 6, 2024
Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer
Denis Moro-Sibilot, Lionel Falchero, Camille Ardin, et al.
ESMO Open
|
August 11, 2018
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
Jaafar Bennouna, Fabrice Barlesi, Pascal Do, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 4, 2021
Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial
Armelle Lavole, Julien Mazieres, Sophie Schneider, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2024
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial
Jean Baptiste Oudart, Simon Garinet, Caroline Leger, et al.
Cancers
|
November 27, 2019
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial
Fatéméh Dubois, Maureen Keller, Julien Hoflack, et al.
JTO Clinical and Research Reports
|
April 20, 2026
Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO
Lionel Falchero, Karim Amrane, Benoît Godbert, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Development and Validation of a Simplified Prognostic Score in SCLC
Elodie Negre, Amandine Coffy, Alexandra Langlais, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 45) with videos related to
Sort By:
Page
of 5
Review of Agricultural, Food and Environmental Studies
|
January 23, 2023
The new Common Agricultural Policy: reflecting an agro-ecological transition. The legal perspective
Alexandra Langlais
The European Respiratory Journal
|
June 2, 2016
Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?
Jacques Cadranel, Marie Wislez, Alexandra Langlais, et al.
Environmental Science and Pollution Research International
|
August 7, 2023
Linking ecotoxicological effects on biodiversity and ecosystem functions to impairment of ecosystem services is a challenge: an illustration with the case of plant protection products
Stéphane Pesce, Annette Bérard, Marie-Agnès Coutellec, et al.
Respiratory Medicine and Research
|
June 6, 2024
Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer
Denis Moro-Sibilot, Lionel Falchero, Camille Ardin, et al.
ESMO Open
|
August 11, 2018
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
Jaafar Bennouna, Fabrice Barlesi, Pascal Do, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 4, 2021
Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial
Armelle Lavole, Julien Mazieres, Sophie Schneider, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2024
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial
Jean Baptiste Oudart, Simon Garinet, Caroline Leger, et al.
Cancers
|
November 27, 2019
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial
Fatéméh Dubois, Maureen Keller, Julien Hoflack, et al.
JTO Clinical and Research Reports
|
April 20, 2026
Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO
Lionel Falchero, Karim Amrane, Benoît Godbert, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Development and Validation of a Simplified Prognostic Score in SCLC
Elodie Negre, Amandine Coffy, Alexandra Langlais, et al.
Page
of 5